This trial is evaluating whether Telotristat Ethyl will improve 1 primary outcome and 8 secondary outcomes in patients with Cancer. Measurement will happen over the course of Baseline to 6 months.
This trial requires 60 total participants across 2 different treatment groups
This trial involves 2 different treatments. Telotristat Ethyl is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 3 and have had some early promising results.
With better treatment and earlier detection, most patients with early-stage cancer can live a normal life for many years and, to a large degree, eliminate symptoms if the disease is detected early. However, patients over 70 years old are much more likely to have a fatal disease. The life expectancy for any individual depends on both the stage of cancer and the patient's ability to deal with the disease and with treatment, whereas the lifespan of the average patient is shortened by cancer compared with the average general population only by a small amount, typically about half a life.
There are some significant racial differences, with blacks/African Americans having nearly half as many cases of [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) but more lung cancer, oesophageal cancer, colorectal cancer, and melanoma. At present, the most common cancers in American women are breast cancer (around 11% of all cases), colorectal cancer (around 7%), ovarian cancer (around 2%), and lung cancer (around 2%); and in men, prostate cancer (around 5%) and colorectal cancer (around 4%).
Cancer treatment in all its forms includes a wide range of non-drug remedies that are often used for adjuvant cancer treatment, cancer symptoms and pain, and pain from cancer treatment. Many patients also seek alternative treatment that does not have a high level of evidence of effectiveness, but many of these practices are also used for common ailments like arthritis and headaches, for which there is some evidence to support them. Patients of all races and sexes seek many of these treatments, making them both widely accessible and the subject of lively community debate.
Signs of cancer can include unexplained weight loss, pain and swelling with breast cancer, a lump or a cancerous lump, feeling tired, feeling thirsty, and feeling warm. The hands and feet are often painful. Symptoms can begin suddenly, and can develop rapidly, in a short period of time. Symptoms can be mistaken for common pains such as a cold, and in many cases they may recur regularly.
Various types of cancer are caused by various factors, including toxins, infection and chemicals. Cancer is caused in some people by a number of different factors. Most cancer causes are inherited from a person's parents.
Cancer is caused by environmental and genetic factors and has many possible symptoms. About half a million people are diagnosed with an active cancer every year. People can make a difference to cancer. Cancer is a cause of death and disability for many people.
Cancer patients are considered research participants and/or clinical research subjects, but are also members of the public by virtue of their cancer condition. As such, it is important to consider the perspectives of participants in the clinical research process. The patients' value-laden priorities should be sought out when making decisions about clinical research for cancer.
In 2005 and in 2006, the average age diagnosed as of any cancer in Australia was 68 years, with the exception of brain and brainstem cancer, where the average age diagnosed was 61.6 years. This shows brain and brainstem cancers are diagnosed later than other cancers, with the exception of breast cancer being the most common cancer diagnosed. Breast cancer was an exception in that it was diagnosed earlier with the average age diagnosed as 61 years. This may be an anomaly and is most likely due to increased screening programs as well as increased awareness of breast cancer.
Telotristat ethyl is occasionally used in combination with gemcitabine in patients with advanced pancreatic cancer. However, the optimal timing of its use and the role of teltristat in the treatment of advanced pancreatic cancer remain to be clearly defined.
Results from a recent clinical trial of this Phase II study suggest that treatment with telotristat etil does not affect survival. We intend to continue evaluation of telotristat etil in patients with advanced or metastatic pancreatic adenocarcinoma.
There is very high survival rates for some types of cancer, including testicular cancer (the most chemosensitive of all cancers), prostate cancer and, of course, breast cancer. However, survival rates are rather low, especially for testicular cancer and, to a lesser degree, lung cancer. Survival rates for colon cancer are among the lowest for any cancer. This pattern can be explained by the various types of cancer, their propensity to spread to other tissues or to other parts of the body (in the case of colon cancer, to lymph nodes or to liver), and/or the types of treatments available and patients’ willingness or ability to get treatment.
Overall, the treatment was well tolerated. In the subset of patients with advanced pancreatic and some stomach cancer, telotristat ethyl showed some potential improvement in time-to-progression and overall survival compared with placebo alone. Clinical trial registered with www.clinicaltrials.gov (NCT01209564).